

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

April 14, 2025

ISSUE No.
1726

IN THIS ISSUE

In Brief: Once-Monthly Lecanemab (*Leqembi*) for Alzheimer's Diseasep 64

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67 (Issue 1726)

April 14, 2025

Take CME Exams

IN BRIEF

Once-Monthly Lecanemab (*Leqembi*) for Alzheimer's Disease

The amyloid beta-directed monoclonal antibody lecanemab-irmb (*Leqembi* – Eisai/Biogen)¹ has now been approved by the FDA for once-monthly use for treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia. It was previously approved only for administration once every 2 weeks. Now, lecanemab can be given every 4 weeks after an 18-month initiation phase of biweekly administration.

CLINICAL STUDIES – FDA approval of the new regimen was based on modeling simulations from one phase 2 and one phase 3 trial (Clarity AD; trials are from the original FDA approval) and their open-label extensions in patients with confirmed amyloid pathology and MCI or mild dementia.^{2,3} Modeling predicted that after 18 months of biweekly lecanemab treatment, transitioning to every 4 weeks would maintain biomarker and clinical effects. The phase 2 trial and its extension found that stopping lecanemab was associated with reaccumulation of amyloid protofibrils and reversion back to the rate of clinical decline observed with placebo.⁴

ADVERSE EFFECTS – The most common adverse effects of lecanemab given every 2 weeks in clinical trials were infusion-related reactions, headache, and amyloid-related imaging abnormalities (ARIA), with

edema (ARIA-E), and with hemosiderin deposition (ARIA-H), which includes microhemorrhage and superficial siderosis. Most cases of ARIA have been detected by scheduled MRIs in asymptomatic patients. The risk of ARIA is greater in patients who are APOE4 homozygotes (~15% of AD patients). Whether administering lecanemab less frequently reduces the risk of ARIA is unknown.

DOSAGE AND COST – The recommended dosage of lecanemab is 10 mg/kg infused intravenously over about 1 hour. One dose of *Leqembi* for a 70-kg patient costs \$897.⁵ Reducing the number of doses by half would result in a significant cost savings. ■

1. Lecanemab (*Leqembi*) for Alzheimer's disease. *Med Lett Drugs Ther* 2023; 65:17.
2. E McDade et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. *Alzheimers Res Ther* 2022; 14:191.
3. CH van Dyck et al. Lecanemab in early Alzheimer's disease. *N Engl J Med* 2023; 388:9.
4. D Selkoe. Does the current evidence for the lecanemab mechanism support a rationale for continued lecanemab dosing? Alzheimer's Association International Conference (AAIC) 2024; Philadelphia, PA, USA and online; July 28-August 1, 2024. Available at: <https://bit.ly/4kz5GhR>. Accessed March 27, 2025.
5. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2025. ISSN 1523-2859

